RC
ACET icon

Rangeley Capital’s Adicet Bio ACET Stock Holding History

Rangeley Capital’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$440K Sell
50,892
-5,108
-9% -$40.3K 0.4% 67
2026
Q1 		$381K Buy
56,000
+30,999
+124% +$232K 0.37% 59
2025
Q4 		$211K Buy
25,001
+20,313
+433% +$225K 0.17% 88
2025
Q3 		$60.8K Buy
+4,688
New +$55.2K 0.05% 116

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Rangeley Capital's ACET Position: Q2 2026 in Review

Rangeley Capital reduced its Adicet Bio (ACET) stake by 9.1% in Q2 2026, selling an estimated $40.3K and leaving 50,892 shares worth $440K. The position accounts for 0.4% of the portfolio, ranked #67.

Rangeley Capital first reported a position in ACET in Q3 2025 and has held it in 4 quarters since. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Rangeley Capital held 50,892 shares of Adicet Bio worth $440K as of Q2 2026.
  • Rangeley Capital sold 5,108 Adicet Bio shares in Q2 2026, an estimated $40.3K.
  • Adicet Bio made up 0.4% of Rangeley Capital's portfolio in Q2 2026, its #67 holding.
  • Rangeley Capital first reported a position in Adicet Bio in Q3 2025 and has held it in 4 quarters since.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.